Description du projet
Un nouveau traitement anticancéreux ciblé
Exploiter le potentiel du système immunitaire pour combattre le cancer constitue une approche thérapeutique attractive. Plus spécifiquement, la conjugaison de médicaments chimiothérapeutiques à des anticorps spécifiques aux tumeurs permet d’améliorer l’administration des médicaments et leur efficacité, tout en minimisant les effets secondaires. Le projet PAC Synthesis, financé par l’UE, propose de combiner les avantages de la dégradation des protéines et le ciblage des anticorps en une nouvelle plateforme thérapeutique. Les scientifiques génèreront des conjugués entre les composés chimères de ciblage de protéolyse (PROTAC) et les anticorps ciblant la protéine myéloïde CD33 dans les cellules de la leucémie aiguë myéloïde. La chimie employée garantit la stabilité des conjugués dans le sang, ainsi que l’efficacité de la libération des PROTAC une fois internalisés par les cellules cancéreuses.
Objectif
The field of immunotherapy has become one of the most promising strategies in fighting cancer. By using the incredible features our very own immune system already possesses, like the powerful tool of specific antibody-antigen recognition, a new generation of drugs can be generated. The idea of linking cytotoxic drugs to monoclonal antibodies with high affinities to specific tumor cells will tremendously improve drug delivery, as tumor-associated antigens can be found by antibodies and the high cytotoxicity of the conjugated drug is used to achieve efficient cancer treatment with less side effects. In this research proposal, we establish a new therapeutic platform that uniquely combines the advantages of two rapidly developing areas – immunotherapy and targeted protein degradation – by developing first class of PROTAC-Antibody Conjugates (PAC). The resulting novel therapeutic agents will help to overcome the limitations arising from lack of cell specificity of PROTACs by exploiting tissue-specificity of the antibody component. Several studies reported encouraging data for the treatment of acute myeloid leukemia (AML) with antibody drug conjugates (ADC) that target the myeloid antigen CD33. In addition, a functionalisable BET inhibitor will be employed in protein degrader construct, generating a new class of small-molecule BET protein degraders. Besides, the proposed self-immolative linker chemistry will allow the traceless realease of the PROTAC once the PAC is internalized into the target cell. Moreover, we will use novel site-selective cysteine bioconjugation approach to build homogenous conjugates that, unlike current examples built using maleimide chemistry, are fully stable in the blood. Overall, this approach will be applicable to any protein of interest and therefore has the potential to advance not only the AML treatment but also the whole field of cancer therapy.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinateur
CB2 1TN Cambridge
Royaume-Uni